Multiple squamous cell carcinomas following introduction of nilotinib.
Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). We assessed a 72-year-old woman who was treated with nilotinib for CML. During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs. Development of SCC is a previously unreported adverse reaction to nilotinib.